CJC-1295: prolonged hormone stimulation
A drug designed to linger left the gland’s pulses intact. I prefer the puzzle of surviving pulses to the usual recovery claims.
Albumin and the DAC form
CJC-1295 was engineered from the first 29 amino acids of growth-hormone-releasing hormone, the signal that prompts the pituitary gland below the brain to release growth hormone. Four substitutions help it resist breakdown. The long-acting DAC form also attaches to albumin, a plentiful blood protein, so its signal can persist for days. The review of growth-hormone-releasing hormone analogues describes this design and its pharmacology.
Borrowing albumin seems wonderfully economical to me. The design also makes duration a safety question: a lingering signal exposes the body for longer, whether or not the hoped-for benefit follows.
Names online often blur that form with Modified GRF 1-29 (sometimes called CJC-1295 no-DAC). The shorter form lacks the albumin-binding feature and lasts minutes to hours. A days-long result from the DAC studies cannot simply travel with the shorter form's name.
The 2006 blood tests
In healthy adults aged 21-61, mean growth hormone rose 2- to 10-fold for at least six days, and IGF-1 rose 1.5- to 3-fold for 9-11 days. IGF-1 is a growth-related hormone made largely by the liver in response to growth hormone. After repeat study administration, IGF-1 remained above baseline for up to 28 days. The estimated CJC-1295 half-life was 5.8-8.1 days.
The companion study of hormone pulses in healthy men aged 20-40 found basal growth hormone about 7.5-fold higher a week later, with mean growth hormone about 46% higher and IGF-1 about 45% higher. The pulses persisted despite continuous stimulation.
The gland’s surviving rhythm overturned my neat expectation of a flattened signal. The gland proved more interesting: changing the input left that pattern present. The studies establish a hormonal response in healthy volunteers. Recovery, muscle gain, improved sleep and healthier ageing would each require their own outcomes and follow-up.
A later study of eleven healthy young men found changes in circulating proteins that correlated with IGF-1. Those candidate markers could help identify hormone-axis activation. The paper gives me another way of detecting an effect, while leaving the health value of that effect open.
Development history and sleep reports
CJC-1295 has no FDA approval, and the original long-acting development programme stopped. A patient death was reported during the development era; the public record did not establish that CJC-1295 caused it. That unresolved history deserves accurate wording rather than a confident causal story.
The early human studies were small and short. Longer exposure raises questions about fluid retention, insulin sensitivity and sustained IGF-1 elevation. An immune response is another concern discussed around long-acting peptide designs and in the broader pharmacology of this hormone family. FDA briefing materials in 2024 also raised immunogenicity and other safety concerns. CJC-1295 is prohibited in tested sport.
Sleep is the benefit most often described in community discussions, followed by workout recovery and gradual changes in body fat. Reports also include puffiness, bloating, tingling hands, local irritation, flushing, fatigue and headache. Some mention higher blood sugar. These accounts are anecdotal, without the clinical comparisons needed to establish their causes.
That clever duration leaves me hungry for evidence about sleep, recovery or everyday function. Researchers could show that a hormone stayed high, while the much larger claim about feeling or ageing better still lacks a large, long human trial. A personal amount or schedule cannot be derived from these experiments.